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Abstract
Background: Multiple sclerosis (MS) is a complex disorder of the central nervous system whose cause is
currently unknown. Evidence is increasing that DNA methylation alterations could be involved in inflammatory
and neurodegenerative diseases and could contribute to MS pathogenesis. Repetitive elements Alu, LINE-1 and
SAT-α, are widely known as estimators of global DNA methylation. We investigated Alu, LINE-1 and SAT-α
methylation levels to evaluate their difference in a case–control setup and their role as a marker of disability.
Results: We obtained blood samples from 51 MS patients and 137 healthy volunteers matched by gender, age
and smoking. Methylation was assessed using bisulfite-PCR-pyrosequencing. For all participants, medical history,
physical and neurological examinations and screening laboratory tests were collected. All repetitive elements were
hypermethylated in MS patients compared to healthy controls. A lower Expanded Disability Status Scale (EDSS)
score was associated with a lower levels of LINE-1 methylation for ‘EDSS = 1.0’ and ‘1.5 ≤ EDSS ≤ 2.5’ compared to
an EDSS higher than 3, while Alu was associated with a higher level of methylation in these groups: ‘EDSS = 1.0’
and ‘1.5 ≤ EDSS ≤ 2.5’.
Conclusions: MS patients exhibit an hypermethylation in repetitive elements compared to healthy controls. Alu
and LINE-1 were associated with degree of EDSS score. Forthcoming studies focusing on epigenetics and the
multifactorial pathogenetic mechanism of MS could elucidate these links further.
Keywords: Multiple sclerosis, Hypermethylation, DNA methylation, Repetitive elements, Epigenetics, Expanded
disability status scale
Background
Multiple Sclerosis (MS) is a neurodegenerative disease
involving the central nervous system (CNS) in which the
infiltration of focal lymphocytes in myelin causes inflamma-
tory lesions leading to axonal damage [1]. MS knows many
different disease courses, of which relapsing-remitting is the
most common one. This course is typed with attacks of
worsening neurological functioning (relapsing), followed by
partial or complete improvement of the symptoms (remit-
ting) [2]. Women are more prone to develop the disease
than men, and the age of onset of the patient ranges mostly
between 20 and 40 years, with a transition to the progressive
forms at the age of 40 to 50 [3].
The causal factors of MS are still poorly understood, but
they are probably heterogeneous [4]. Recent findings sug-
gest that the interplay between individual genetic
susceptibility and external, environmental influences modu-
late the disease presentation and therapeutic responsiveness
[5, 6]. Evidence is increasing that epigenetic mechanisms
could be involved in inflammatory and neurodegenerative
diseases and some studies have suggested that changes in
these mechanisms could contribute to MS pathogenesis,
representing a bridge between genetics and environmental
causal factors [7]. Epigenetics are stable and heritable pat-
terns that modify the phenotype without altering the geno-
type. In particular, DNA methylation has been the most
extensively studied epigenetic marker. It involves adding a
methyl group to the 5′ cytosine located in a CpG site to form
5 methylcytosine (5mC). A recent study from Huynh et al.
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found that genes important in oligodendrocyte survival were
hypermethylated and had a lower expression in MS-affected
human brain tissue compared to controls [8]. Furthermore,
studies have shown a relation between repetitive elements
hypermethylation and adverse health outcomes [9, 10].
Repetitive elements comprise roughly 66–69 % of the
human genome [11]. It is estimated that one million Alu
repeats are present in the human genome, which accounts
for over 10 % of the entire genome [12], while 20 % are
long interspersed nuclear element 1 (LINE-1) repeats [13]
and 3–5 % comprises of alpha satellite DNA sequences
(SAT-α) [14]. SAT-α sequences can be found in centro-
meres or centromere-adjacent heterochromatin contain-
ing several CpG sites [15]. The methylation status of these
sequences might be considered a good estimate for global
DNA methylation levels, and have been previously investi-
gated in relation to human diseases [16, 17]. Hitherto
there is limited information about Alu, LINE-1 and SAT-α
methylation in MS. Consequently, this study aims to
evaluate the changes in methylation of these repetitive ele-
ments using a quantitative approach.
In the present study, we estimated repetitive element
methylation levels in a population of 51 MS patients and
137 healthy controls matched for gender, age, and smoking
status. These matching phenotypes were selected as they
have been linked with differential methylation [18]. Methyla-
tion of Alu, LINE-1 and SAT-α was evaluated in association
with MS course markers (i.e. Multisystem Deficits at disease
onset, presence of oligoclonal bands in cerebrospinal fluid,
CSF) and Expanded Disability Status Scale (EDSS). Quanti-
tative bisulfite-polymerase chain reaction (PCR)-pyrose-
quencing was applied to determine methylation levels of
Alu, LINE-1 and SAT-α.
Methods
Study design
Adult patients with MS (n = 51) were recruited at the
Dino Ferrari Center, Fondazione Ca’ Granda, IRCCS
Ospedale Maggiore Policlinico in Milan, from January to
December 2010. Clinical diagnosis was performed using
the McDonald criteria and their subsequent revisions
[19–21]. All patients received standard clinical examina-
tions, including medical history check, physical and
neurological examinations, screening laboratory tests and
a brain magnetic resonance imaging (MRI). Healthy con-
trol subjects (n = 137), matched for age, gender, smoking
habits and ethnic background, were enrolled at the Depart-
ment of Preventive Medicine, IRCCS Ospedale Maggiore
Policlinico in Milan. Written informed consent was signed
by each participant.
Healthy volunteers donated a blood sample at time of
recruitment, while the MS patients donated blood at
least one month after the completion of their steroid
treatment following neurological symptoms. MS patients
in remitting phase donated a single blood sample, while
patients that were in the relapse phase during the first col-
lection donated a second blood sample one month after
an acute phase. Genomic DNA from 3 ml whole-blood
was extracted using a FlexiGene DNA Kit (Qiagen Inc.,
Hilden, Germany), following manufacturer’s instructions.
The DNA concentration in each sample was determined
measuring the optical density (OD) at 260 nm wavelength
on a NanoDrop 1000 Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA). DNA samples were ali-
quoted and stored at −20 °C until further measurements.
Analysis of DNA methylation
DNA methylation was quantified using bisulfite-PCR and
pyrosequencing. In short, each sample (concentration 50
ng/μl) was treated using the EZ DNA Methylation Gold™
kit (Zymo Research, Orange, CA, USA). Final elution was
performed in 30 μl of M-Elution Buffer. Bisulfite treated
samples were used to assess DNA methylation of repeti-
tive elements according to Yang et al. [16]. PCR primers
were designed towards a consensus Alu, LINE-1, and SAT-
α, and allowed the amplification of a representative pool
of repetitive elements as a surrogate for global DNA
methylation changes. PCR was carried out in 50 μl of Go-
Taq Green Master Mix (Promega, Madison, WI, USA)
with 1 pmol of the forward primer, 1 pmol of the reverse
primer, 50 ng of bisulfite-treated DNA and water. Per
primer pair (Table 1) either the forward or reverse primer
was biotin labelled to purify the final PCR product by
binding them to Streptavidin Sepharose HP beads (Amer-
sham Biosciences, Uppsala, Sweden). The beads contain-
ing the bound PCR product were purified using the
Pyrosequencing Vacuum Prep Tool (Pyrosequencing Inc.,
Westborough, MA, USA). The degree of methylation
(%5mC) for each DNA locus is reported as a percentage
of methylated cytosines divided by the sum of methylated
and unmethylated cytosines. Samples were tested in tripli-
cate for each marker to confirm reproducibility of the
Table 1 Sequences of the primers for Alu, LINE-1 and SAT-α from left to right are from 5′ to 3′. Biotinilation (BIO) of the primers occurred
at the 5′ end. Forward and reverse primers were utilized in the PCR step while the sequencing primer was used during pyrosequencing
Primer (5′ to 3′) Alu LINE-1 SAT-α
Forward BIO-TTTTTATTAAAAATATAAAAATT TTTTGAGTTAGGTGTGGGATATA BIO-TGGATATTTGGATTATTGG
Reverse CCCAAACTAAAATACAATAA BIO-AAAATCAAAAAATTCCCTTTC TTTCCAAAAAAATCTTCAAAAAAAT
Sequencing AATAACTAAAATTACAAAC AGTTAGGTGTGGGATATAGT CTCAAAAATTTCTAAAAATACTTCTC
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results. Concordance correlation coefficient obtained from
duplicate runs was 0.518, 0.349 and 0.473 for Alu, LINE-1
and SAT-α respectively.
Statistical analysis
A descriptive analysis was performed on demographic and
clinical characteristics. Mean and standard deviation were
reported for continuous variables, count and percentage
for categorical variables. Mean age and mean levels of
methylation markers: Alu, LINE-1 and SAT-α were com-
pared between MS patients and healthy controls by means
of t-test.
Characteristics of MS patients and healthy controls were
compared using the Chi-Square test or Fisher’s exact test
for categorical variables and for continuous variables by the
t-test. Correlation between three methylation markers in all
participants was assessed with the Pearson correlation coef-
ficient test. The same test was used to evaluate this correl-
ation in controls and in MS patients. We computed odds
ratios (ORs) and 95 % confidence intervals (CI) for the
association of methylation levels with case/control status
using multivariable logistic regression models, adjusted for
age, gender and smoking status.
In order to investigate the potential association between
disability status and the repetitive elements in MS patients,
study participants were distributed equally between three
groups according to their EDSS score: ‘EDSS = 1.0’, ‘1.5 ≤
EDSS ≤ 2.5’ and ‘3.0 ≤ EDSS ≤ 7.5’. Adjusted multivariable
linear regression analyses was carried out to evaluate the
relationship between the level of methylation in repetitive
elements and EDSS score. The assumptions underlying the
linear regression model (i.e. linearity, normality and homo-
scedasticity) were satisfied for all the independent continu-
ous variables. Coefficients (ß) and 95 % CI were calculated
firstly using ‘3.0 ≤ EDSS ≤ 7.5’ as reference for the other
two groups and secondly using ‘EDSS = 1.0’ as the refer-
ence. Adjusted means and 95 % CI were also calculated and
compared for each methylation marker.
Linear regression (adjusted for sex, age and smoking
status) was applied to investigate the relationship between
methylation marker level and disease activity, year of neuro-
logical symptoms onset, multisystem disorder, presence of
oligoclonal bands, presence of multiple bands in CSF and
spinal cord relapse. Statistical analysis was carried out using
SAS software (version 9.2, SAS Institute, Milan, Italy). A
two-sided p-value of less than 0.05 was considered statisti-
cally significant.
Results
Characteristics of the study population
Table 2 shows the characteristics of the 51 MS patients
and 137 healthy control subjects. The mean age of the
patients and control group was 39.6 and 41.4 years,
respectively. Both groups had more female participants
than male (25.5 % and 27.0 % for the patients and con-
trols, respectively) while most of the subjects declared
to be non-smokers (62.5 % of the MS patients and 62.0
% of the control group). Among MS patients, 58.8 %
have had only one episode of neurological symptoms,
while 41.2 % had at least two episodes. Thirty-eight
percent of the patients had an EDSS score of 1 (38 %),
34 % a score between 1.5 and 2.5, and 30.0 % had a se-
vere EDSS score of 3.5 to 7.
Table 2 Characteristics of Multiple Sclerosis (MS) patients and
healthy controls
Characteristics MS patients Healthy controls p-value
n = 51 n = 137
Age (years)
Mean ± SD 39.6 ± 8.1 41.4 ± 9.1 >0.1
Gender
Female 38 (74.5) 100 (73.0) >0.1
Male 13 (25.5) 37 (27.0) -
Smoking habita
Yes 15 (35.3) 52 (38.0) >0.1
No 33 (64.7) 85 (62.0) -
Neurological episodes
Only one 30 (58.8) -
At least two 21 (41.2) -
Disabilityb
EDSS = 1.0 18 (36.0) -
1.5 ≤ EDSS ≤ 2.5 17 (34.0) -
3.0 ≤ EDSS ≤ 7 15 (30.0) -
Onset of MS
1981 – 1999 18 (35.3) -
2000 – 2004 15 (29.4) -
2005 – 2010 18 (35.3) -
Multisystem deficits at onset
Yes 14 (27.5) -
No 37 (72.5) -
Oligoclonal Bands in CSFc
Yes 44 (89.8) -
No 5 (10.2) -
Methylation markers (%5mC)
Alud 25.3 ± 0.6 24.5 ± 1.1 <0.001
LINE-1 85.1 ± 1.4 82.6 ± 2.8 <0.001
SAT- α 80.3 ± 2.6 78.9 ± 2.8 0.014
Data is presented as Mean ± SD or number (%). Disability is defined as
‘expanded disability status scale’ (EDSS)
Statistical comparison: student t-test between MS patients versus healthy
controls: age and methylation markers. Chi-Square, total population: gender
(50 males versus 138 females) and smoking habit (67 smokers versus
118 non-smokers)
aData available for: 48, b50 and c49 MS patients and d135 healthy controls
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Internal correlations of repetitive elements
Considering the entire study population, Alu methylation
level was positively correlated with the methylation level of
both LINE-1 (ρ = 0.614, p < 0.0001) and SAT-α (ρ = 0.259,
p = 0.0003). LINE-1 methylation was also positively corre-
lated with SAT-α (ρ = 0.553, p < 0.0001). After case/control
stratification, these correlations were confirmed in the con-
trol group (Alu and LINE-1: ρ = 0.627, p < 0.0001; Alu and
SAT-α: ρ = 0.253, p = 0.0003; LINE-1 and SAT-α: ρ = 0.559,
p < 0.0001). Conversely, in the MS patients group (Fig. 1),
only LINE-1 methylation was correlated with the degree of
methylation in SAT-α (ρ = 0.380, p < 0.0059). Alu methyla-
tion levels were not correlated with the methylation of
either LINE-1 (ρ = −0.015, p = 0.285) or SAT-α (ρ = −0.025,
p = 0.861).
Differences in methylation levels in MS patients and healthy
control subjects
As shown in Table 1, all methylation markers showed a
significant increase in methylation in the MS patients group
compared to the healthy control group. Alu methylation
was 25.3 % 5mC in MS patients and 24.5 % 5mC in healthy
controls (p < 0.0001). LINE-1 methylation was 85.1 %5mC
in MS patients and 82.6 % 5mC in the healthy controls
(p < 0.0001). SAT-α methylation was 80.3 % 5mC in MS
patients and 78.9 %5mC in healthy controls (p < 0.003).
The difference between cases and controls remained
significant after adjusting for age, gender and smoking
status in a multivariate logistic regression analysis for
all markers (Alu: p = 0.0029; LINE-1: p = 0.0003; SAT-
α: p = 0.0456), respectively the OR for Alu, LINE-1 and
SAT-α were 2.137, 1.619 and 1.155. CpG site specific
analyses are shown in Additional file 1: Figure S1 and
their characteristics are presented in Additional file 2:
Table S1.
Methylation levels in EDSS in MS patients
When we compared EDSS classes, using the highest EDSS
class as reference, Alu methylation was elevated in both
‘EDSS = 1.0’ (ß = 0.47; 95 % CI = 0.04 to 0.90; p = 0.034)
and ‘1.5 ≤ EDSS ≤ 2.5’ (ß = 0.63; 95 % CI = 0.18 to
1.08; p = 0.007). LINE-1 methylation was lower in
both ‘EDSS = 1.0’ (ß = −0.95; 95 % CI = −1.89 to
0.003; p = 0.050) and ‘1.5 ≤ EDSS ≤ 2.5’ (ß = −1.07;
95 % CI = −2.06 to −0.09; p = 0.033). SAT-α methylation
was not significantly different in the EDSS groups. Results
are shown in Fig. 2.
Methylation levels and MS course
No significant differences were observed in the methyla-
tion markers between subjects who experienced just one
neurological episode or at least two episodes. There was
no significant association between methylation and years
of onset. Furthermore, no differences were observed be-
tween methylation and multisystem disorders. The presence
or amount of oligoclonal bands in CSF was also not associ-
ated with repetitive element methylation. Finally, no signifi-
cant differences were found between patients with and
without spinal cord relapse. Data is presented in Additional
file 3: Table S2.
Fig. 1 Scatter plot comparing Alu, LINE-1 and SAT-α methylation levels. In panel a, the correlation is represented for the MS patients, in panel b
for the healthy controls. For the latter group, all repetitive elements were significantly correlated with each other in terms of methylation (Alu and
LINE-1, ρ = 0.627; Alu and SAT-α, ρ = 0.253; LINE-1 and SAT-α, ρ = 0.559). In the MS patients, only LINE-1 methylation was significantly correlated
with SAT-α methylation (ρ = 0.380). Significance level was set at 0.05
Neven et al. BMC Genetics  (2016) 17:84 Page 4 of 7
Discussion
In the present study, we evaluated methylation levels of Alu,
LINE-1 and SAT-α in 51 MS patients and 137 healthy volun-
teers. MS patients showed hypermethylation in all repetitive
elements compared to healthy controls. Furthermore, the
correlations between these global methylation markers in
the control group were lost in MS patients. Moreover, we
demonstrated that worsening disability score was associated
with hypomethylation in Alu and hypermethylation in
LINE-1. These findings suggest that MS patients have an
altered methylation of repetitive elements in blood leuko-
cytes compared to healthy individuals. To our knowledge,
this is the first study to investigate associations between
methylation of Alu, LINE-1 and SAT-α, and MS.
Previous research found associations of global DNA
hypermethylation with neurodegenerative and neuro-
logical disorders like Alzheimer’s disease [22, 23] and post-
traumatic stress disorder [24]. However, the pathogenesis
for MS is different from these disorders. Furthermore, a
recent case–control study concerning genome-wide DNA
methylation in MS patients finds immune cells to experi-
ence hypermethylation [25]. A second epigenetic mechan-
ism involved in MS are micro RNAs (miRNA). These
miRNAs are involved in gene silencing by degrading target
mRNA sequences to prevent their translation into pro-
teins. Literature suggest that certain miRNA (e.g. miR-155
and miR-326) are highly upregulated in active MS lesions
[26]. This upregulation can in turn lead to macrophage
activation, myelin degradation and could drive the MS
progression [7, 27]. Furthermore, dysregulation of miR-
155 and miR-326 has been observed in peripheral blood
mononuclear cells and CD4+ T cells of MS patients
respectively [7]. We found all repetitive elements to be
hypermethylated in MS patients compared to the healthy
controls. Since these repetitive elements are a marker for
global DNA methylation levels, our results suggest that in
MS the genome exhibits a higher degree of methylation.
While a hypermethylation would indicate a downregula-
tion of miR-155 and miR-326, no hypermethylation was
observed in CD4+ T cells of MS patients, only in CD8+ T
cells [28].
Healthy controls showed significant correlations among
the degree of methylation for all repetitive elements, while
in patients with MS only LINE-1 and SAT-α methylation
levels remained significantly correlated. We speculate that
for healthy subjects the upkeep mechanisms for these
elements are able to maintain the normal methylation
levels, while in MS patients these upkeep regulations
might be partially lost. This could in turn lead to an ab-
normal maintenance of repetitive element methylation
levels causing their reciprocal correlations to diminish.
We observed different methylation levels in Alu and
LINE-1 among the three different EDSS groups. Methyla-
tion of Alu decreased with increasing EDSS scores. Al-
though this tendency was also observed in SAT-α, it was
not significant. In contrast, LINE-1 methylation was posi-
tively associated with EDSS score. These results could be
counterintuitive as both Alu and LINE-1 are markers of
global DNA methylation and are positively correlated with
each other. However, as mentioned earlier, in MS patients
this correlation disappears and they tend to be inversely
(but not significantly) associated. Prior studies find that
EDSS value is strongly correlated with axonal damage and
neurodegeneration [29, 30]. Furthermore, a possible
Fig. 2 Methylation levels of Alu, LINE-1 and SAT-α in MS patients, grouped by Expanded Disability Status Scale (EDSS), are represented as box plots. Data
were adjusted for age, sex and smoking habit. All groups had a similar number of individuals: 18 participants for ‘EDSS = 1.0’, 17 for ‘1.5 ≤ EDSS ≤ 2.5’
and 15 for ‘3.0 ≤ EDSS ≤ 7.5’. For both Alu and LINE-1 the highest EDSS group (the reference) was significantly different from the lower two groups. An
absolute difference in methylation of 0.47 %5mC can be observed for ‘EDSS = 1’ (p = 0.034) and 0.63 %5mC for ‘1.5 ≤ EDSS ≤ 2.5’ (p = 0.007) compared
with the reference group for Alu. In LINE-1, methylation decreased with 0.95 %5mC for ‘EDSS = 1’ (p = 0.050) and 1.07 % for ‘1.5 ≤ EDSS ≤ 2.5’ (p = 0.033)
compared to the reference group. * p < 0.05
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mechanism for MS progression and axonal loss could be
via oxidative stress, caused by a decrease in antioxidant
levels, which might lead to DNA damage [31]. A possible
mode of action is through DNA methyl-transferase
(DNMT), which are recruited to sites of DNA damage and
have previously been suggested as being directly involved in
DNA damage repair [32]. These DNMTs have been re-
ported as important and essential elements in development
and are responsible for genomic integrity due to their
methylating capabilities [32, 33]. As Bollati et al. proposed,
a LINE-1 hypermethylation could be the consequence of
this DNMT upregulation [22]. The effect of DNMT overex-
pression was observed in brain tissue of mice, where they
associated this upregulation with an increase in methylation
in motor neuron cells [34].
Although we found MS patients to have hypermethy-
lated repetitive elements, no distinct methylation differ-
ences were observed in different clinical MS groups (i.e.
disease activity, phase of MS, days since relapse, year of on-
set, multisystem disorder, spinal cord relapse and the pres-
ence of oligoclonal bands in CSF). Our data had a limited
amount of MS patients in different clinical groups, which
might contribute to non-significant results.
Conclusion
As MS has a multifactorial pathology, hypotheses focus-
ing solely on environmental or genetic components are
missing key components. However, epigenetics are able
to bridge the gap between these theories and appears to
be promising. In summary, we found that 1) Alu, LINE-1
and SAT-α repetitive elements were hypermethylated in
MS patients, 2) Alu, LINE-1 and SAT-α are positively cor-
related with each other in healthy controls, while only
LINE-1 and SAT-α are correlated in MS patients and 3)
EDSS values were associated with differential methyla-
tion in Alu and LINE-1 elements. We suggest that forth-
coming investigations should include a higher number of
MS patients to increase statistical power. Future studies
focusing on epigenetics and both disease course and clin-
ical prognostic markers could further elucidate the un-
derstanding of the multifactorial pathology of MS.
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